Chief Executive Officer


Marshall Hartmann brings passion and an inextinguishable enthusiasm to the Okra team.  A South Carolina native, Marshall quickly established a successful career in banking after graduating from the University of South Carolina with a degree in finance. He leveraged that experience to launch a new career in residential and commercial development where he focused his efforts for nearly 30 years.  Over the past decade, Marshall and his brother have started two companies, Okra Medical and an innovative electronics manufacturer that has sustained 50% growth each year.


Chief Technology Officer

By the time Justin Stas began pursuing a degree in biomedical engineering, he already spent more than a decade learning about anesthesia and pain management from his father, a thought leader in these fields. Throughout his studies, Justin developed an expertise on the intricacies of chemical compounds. After his formal studies, he spent years tirelessly pursuing a formula to neutralize controlled substances. Much of his research was conducted in tandem with a multi-disciplinary team that has years of cumulative experience in pharmaceutical research.  With the launch of Okra Medical, Justin is experiencing his mission of improving humanity through innovation.


Chief Medical Officer

Dr. John Stas is a retired Army Officer that has decades of acute pain management experience. He has led anesthesia departments to reduce opioid consumption with alternative pain management methods. Additionally, he spent ten years in civil service as both an anesthesia leader and developing a state-of-the-art pain management practice for combat casualties. Dr. Stas has been teaching advanced regional anesthesia both clinically and didactically for many years in multiple areas to include the University of South Carolina Anesthesia Program and holds a faculty position for Twin Oaks Anesthesia. He is an expert with ultrasonography in the field of regional anesthesia and acute pain management.  Dr. Stas graduated from the Medical University of South Carolina and received both a master’s degree from the U.S Army Graduate Program in Anesthesia and a Doctorate from Texas Wesleyan University.


Chief Financial Officer

Ed Hartmann brings more than 30 years of experience in financial management, leadership and consulting to the Okra Medical team.  Ed previously served as V. P. and Controller for Curacao International Trust Corporation in St. Thomas and more recently as the V.P. of Finance for Crowley Maritime, Inc., a $2 billion ocean freight transportation and logistics company. Ed received a Bachelor of Science degree in International Finance from Florida State University and an MBA and DBA in organizational leadership.  Ed thrives at optimizing financial performance, raising debt and equity capital, strategic planning, and integrating acquisitions.

Mark has held leadership positions in global contract research organizations (CROs) for the past 23 years. Throughout Mark’s CRO career, his teams have developed industry-leading client relationships teams to support approvals for numerous blockbuster drugs and medical devices, including three of the world’s top-selling drugs.  As the leader of Avomeen, Mark works closely with the senior leadership and project teams to ensure the company delivers exceptional and innovative hard-to-solve product development challenges, while ensuring compliance with rigorous regulatory standards such as cGMP, cGLP and other industry standards.

Mark Harvill, CEO, Avomeen Analytical

Andrew has 20 years of experience executing and managing analytical and product development programs, both internally and in external organizations.  His expertise is analytical chemistry in highly regulated areas including pharmaceutical development and testing, food contact migration studies, extractables and leachables studies, food additive and food contact notification testing and registration, and pesticide and insecticide testing under FIFCA.  He has served as an expert witness to support litigation in the areas of pharmaceutical development and analytical testing.  He has participated in FDA pre-notification conferences, FDA site audits, and trained FDA inspectors on analytical technology.

Andrew Kolbert, PhD, M.T.M., President and CEO, Avomeen Analytical

David is the CEO of Incremental Advantage. He is recognized world-wide for his expertise in valuing emerging technologies and intangible assets such as patents, trademarks, copyrights, contracts, earn-outs and non-compete agreements. His clients include emerging, mid- and large-sized companies; technology transfer offices; inventors; venture capitalists and private equity firms. David is the author of seven books. The most recent of which are Plight of the Patentee, Solution Nation: One Nation is Disproportionately Responding to the World ‘s Most Intractable Problems, The Strategic Negotiator: A Manual for Negotiating at the Elite Level, and Business Model Validation.

David Wanetick, CEO, IncreMental Advantage 

* Certain controlled substances that are also regulated by the EPA are pending EPA concurrence.

3538 Meeks Farm Rd
Johns Island, SC 29455



  • White LinkedIn Icon
Okra Medical
 2019 InnoVision Finalist
© 2020 Okra Medical, Inc.  All rights reserved in all countries. 
SAFEMEDWASTE™ and Okra Medical™ are trademarks of
Okra Medical, Inc. 
Okra Medical is DEA Registered.